Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Income from Continuing Operations: 2023-2025

Historic Income from Continuing Operations for CG Oncology (CGON) over the last 3 years, with Sep 2025 value amounting to -$43.7 million.

  • CG Oncology's Income from Continuing Operations fell 114.22% to -$43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.4 million, marking a year-over-year decrease of 107.99%. This contributed to the annual value of -$88.0 million for FY2024, which is 81.36% down from last year.
  • As of Q3 2025, CG Oncology's Income from Continuing Operations stood at -$43.7 million, which was down 5.52% from -$41.4 million recorded in Q2 2025.
  • CG Oncology's 5-year Income from Continuing Operations high stood at -$8.7 million for Q1 2023, and its period low was -$43.7 million during Q3 2025.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$18.9 million (2024), whereas its average is -$23.3 million.
  • Data for CG Oncology's Income from Continuing Operations shows a maximum YoY crashed of 119.05% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows CG Oncology's Income from Continuing Operations stood at -$16.6 million in 2023, then slumped by 92.16% to -$31.8 million in 2024, then plummeted by 114.22% to -$43.7 million in 2025.
  • Its Income from Continuing Operations was -$43.7 million in Q3 2025, compared to -$41.4 million in Q2 2025 and -$34.5 million in Q1 2025.